ReviewCancers2022
Cannabidiol (CBD) in Cancer Management.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Potential antitumor effect of cannabidiol (CBD) in canine oncology: a systematic review.Frontiers in veterinary science · 2026Pooled it
- Cannabidiol as a novel therapeutic agent in breast cancer: evidence from literature.BMC cancer · 2025Pooled it
- Modulation of the endocannabinoid system reduces inflammatory signalling in canine mammary carcinoma cells.Veterinary record open · 2026Article
- Solubility-improved and antitumor activity of (-)-cannabidiol conjugates.Journal of cannabis research · 2026Article
- The Effect of Cannabidiol on Cancer-Pathway Genes in Doxorubicin-Sensitive and Resistant Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cannabidiol modulates exosomal miRNA networks to enhance Imatinib mesylate response in chronic myelogenous leukemia.Global medical genetics · 2026Article
- The differential effects of CBD and CBDA on viability and mRNA expression in colorectal cancer cells.Journal of cannabis research · 2026Article
- Cannabidiol-Ion Channel Interactions Represent a Promising Preventive and Therapeutic Strategy in Hepatocellular Carcinoma.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Cannabidiol in Gliomas: Therapeutic Potential and Nanocarrier Strategies, with an Emphasis on Vesicular Delivery Systems.Molecular pharmaceutics · 2026Review
- Cannabidiol Regulates CD47 Expression and Apoptosis in Jurkat Leukemic Cells Dependent upon VDAC-1 Oligomerization.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- Nutritional Impact on Breast Cancer in Menopausal and Post-Menopausal Patients Treated with Aromatase Inhibitors.Cancers · 2025Review
- Cannabidiol does not cause DNA double-strand breaks in a human liver-derived cell model.Journal of cannabis research · 2025Article
- Cannabidiol sensitizes triple-negative breast cancer cells to NK cell-mediated killing via EGFR inhibition and FAS upregulation.Journal of cannabis research · 2025Article
- Tobacco and other substance co-use among adolescents and young adults with cancer who use tobacco: prevalence and associations with nicotine dependence and depression.Family medicine and community health · 2025Article
- The Role of the Endocannabinoid System in Oncology and the Potential Use of Cannabis Derivatives for Cancer Management in Companion Animals.Animals : an open access journal from MDPI · 2025Review
- Cannabidiol (CBD) and Colorectal Tumorigenesis: Potential Dual Modulatory Roles via the Serotonergic Pathway.Current oncology (Toronto, Ont.) · 2025Review
- Review
- Cannabidiol (CBD) as a potential therapeutic agent for liver cancer: a comprehensive review of current evidence.Cancer cell international · 2025Review
- Proteomic Analysis of Invasive Breast Cancer Cells Treated with CBD Reveals Proteins Associated with the Reversal of Their Epithelial-Mesenchymal Transition Induced by IL-1β.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plant Cannabis sativa has been in use medicinally for several thousand years. It has over 540 metabolites thought to be responsible for its therapeutic effects. Two of the key phytocannabinoids are cannabidiol (CBD) and tetrahydrocannabinol (THC). Unlike THC, CBD does not have potentially intoxicating effects. Preclinical and clinical research indicates that CBD has a wide range of therapeutic effects, and many of them are relevant to the management of cancer. In this article, we explore some of the potential mechanisms of action of CBD in cancer, and evidence of its efficacy in the integrative management of cancer including the side effects associated with its treatment, demonstrating its potential for integration with orthodox cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.